SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021)
SELLAS Life Sciences (SLS) posted quarterly Current Deferred Revenue of $900000.0 for Q1 2021, down 83.93% quarter-over-quarter from $5.6 million in Q4 2020.
SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Current Deferred Revenue for 3 consecutive years, with $900000.0 the latest figure, recorded in Q1 2021.
- In Q1 2021, Current Deferred Revenue changed N/A year-over-year to $900000.0; the TTM figure through Mar 2021 stood at $900000.0 (changed N/A YoY), while the FY2020 annual figure was $5.6 million, changed N/A from the prior year.
- Current Deferred Revenue fell to $900000.0 in Q1 2021 per SLS's latest filing, from $5.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $5.6 million in Q4 2020 and bottomed at $900000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 900,000.00 |
| Dec 31, 2020 | 5.60 Mn |
| Dec 31, 2011 | 816,000.00 |
| Sep 30, 2011 | 877,000.00 |
| Jun 30, 2011 | 578,000.00 |